Evommune, a clinical-stage biotechnology company listed on the NYSE, has agreed to sell 4,966,889 shares of common stock in a private placement at $6.04 each. Gross proceeds are expected to be about $30 million before expenses. The investors include Adage Capital Partners, Balyasny Asset Management, Defilade Capital Management, OrbiMed, and Squadron Capital Management, along with other healthcare-focused funds. The deal is expected to close on or about November 6, 2026, subject to customary conditions. Evommune will use the money to advance its clinical programmes, including EVO570, a newly in-licensed oral VAV1-directed molecular glue degrader, and for general corporate purposes. Morgan Stanley and Leerink Partners acted as placement agents. Oppenheimer was capital markets advisor.

Evommune announces $30 million private placement. Key Takeaway: Evommune, Inc. announced a $30 million private placement to sell nearly 5 million shares at $6.04 each. The funds will support the clinical development of its therapies, including EVO570, and general corporate purposes. The placement is expected to close around November 6, 2026, pending customary conditions. Market sentiment analysis. Positive factors. * Evommune raised $30 million through a private placement. * The funding will advance clinical development programs. * Participation from reputable institutional investors. * The company aims to improve therapies for chronic inflammatory diseases. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 2 past catalysts Cash runway Low dilution risk Lead asset Phase 2 · Atopic Dermatitis (AD) PALO ALTO, Calif. & NEW YORK-(BUSINESS WIRE)- Evommune, Inc. ("Evommune" or the "Company") (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $6.04. Evommune anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any transaction-related expenses. The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions. The financing includes participation from both new and existing institutional investors, including Adage Capital Partners, L.P., Balyasny Asset Management, Defilade Capital Management, OrbiMed, Squadron Capital Management and other fundamental healthcare dedicated funds. Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents for the private placement. Oppenheimer & Co. Inc. acted as capital markets advisor for the private placement. Evommune intends to use the net proceeds from the private placement to advance its clinical development programs, including EVO570, its newly in-licensed oral VAV1-directed molecular glue degrader, and for general corporate purposes. The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. Concurrently with entering into the securities purchase agreement, Evommune and the investors entered into a registration rights agreement pursuant to which Evommune has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Evommune, Inc. Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. Forward-Looking statements. This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning expected proceeds from the private placement, expected use of proceeds, and expected closing of the private placement. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company's ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company's ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Investors and media: megan humphreys [email protected]. Released November 4, 2026 Frequently asked questions. What is the amount raised in Evommune's private placement? Evommune raised approximately $30 million through the private placement. Who are the investors in the private placement? The placement includes both new and existing institutional investors. What will the funds be used for? The funds will support clinical development programs and general corporate purposes. When is the private placement expected to close? The private placement is expected to close on or about November 6, 2026.

Evommune announces late-breaker Presentation of Phase 2a data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress. PALO ALTO, Calif. & NEW YORK-(BUSINESS WIRE)- Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Austria from September 30 to October 3, 2026. EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed to neutralize aberrantly upregulated IL-18 activity. IL-18 sits upstream of the Th2 axis and modulates Th1, Th2, Th17/22 and innate inflammatory pathways. "Twenty-nine million patients still need advanced therapy for their moderate-to-severe AD.[1] IL-18 inhibition has clinically demonstrated its ability to impact the Th2 drivers of AD, consistent with current standard of care. Additionally, targeting IL-18 offers a novel, upstream approach that goes beyond Th2, addressing multiple broad inflammatory pathways and resulting in its potential to serve a broad spectrum of patients in this highly heterogeneous disease," said Luis Peña, President and Chief Executive Officer at Evommune. "We look forward to sharing the Phase 2a data at EADV, building on the topline results we reported earlier this year. The Phase 2b dose-ranging study for EVO301 in moderate-to-severe AD, anticipated to begin in mid-2027, advances a core component of our broad inflammatory disease focused pipeline." Late-Breaking Oral Presentation Title: Positive Top-line Data from the Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis Session: D2T01.4 - Late Breaking News Presenter: Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai Date: Thursday, October 1 Time: 4:30-4:45 pm CEST / 10:30-10:45 am EDT Location: Hall A About IL-18 IL-18 is a known inflammatory pathway which plays a key role in various immune processes and acts as a key upstream therapeutic target for AD and other chronic inflammatory diseases. As an alarmin cytokine, IL-18 acts as a general amplifier of inflammation, capable of driving multiple inflammatory responses, including Th1, Th2, Th17/22 and innate pathways. This upstream position is crucial for treating conditions with heterogeneous inflammation, where targeting a single pathway may not be optimal. An upregulated IL-18 pathway cyclically activates inflammatory mediators in an aberrant manner, resulting in tissue damage and other inflammatory pathology. IL-18 directly disrupts essential barrier functions, positioning it as a pivotal pathogenic factor. Targeting IL-18 offers a novel broader therapeutic utility, simultaneously reducing inflammation and restoring tissue integrity for patients with complex inflammatory conditions. About EVO301 EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. Evommune believe EVO301 has the potential to facilitate more efficient tissue distribution and improved activity relative to existing attempts to antagonize or inhibit the IL-18 pathway. In addition, EVO301 incorporates several distinguishing design features, including selective and high binding affinity of native human IL-18BP and binding to serum albumin, smaller molecular weight, extended half-life for the neutralization of IL-18, and lower potential for immunogenicity. Evommune believes the distinct mechanism and modality of EVO301 provides multiple, potentially synergistic avenues to bring innovative therapeutics to the large, underserved and rapidly expanding population of patients suffering from chronic inflammatory diseases. About Evommune, Inc. Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow Evommune on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO301; the design, objectives, initiation, timing and progress of the Phase 2b clinical trials evaluating EVO301 in AD; and continued advancement of the Company's portfolio. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company's ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company's ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K, filed with the SEC on March 5, 2026, as supplemented by the Company's Quarterly Report on Form 10-Q, filed with the SEC on August 6, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.